SABCS 2021

Metformin is not an anti-cancer drug

Leading the way for other ct-DNA trials

The risk-adapted decision for or against AI has to be…

The next standard for TNBC?!

Benefit only related to chemotherapy?!

Hypothesis-generating study in the HER2-enriched…

Molecular-guided treatment is of value in combination…

Re-evaluation confirms old data

Critical consideration of the study data is necessary

Negative results with hope for translational projects

Solved and unsolved controversies of early breast…

Genomic signatures of DCIS

Metformin shows no efficacy for most cancer patients

Kritische Betrachtung der Studiendaten notwendig

Genomisch gesteuererte Therapie sinnvoll in Kombi mit…

Muss die risiko-adaptierte Entscheidungsfindung bei AI…

Hypothesen-generierende Studie beim HER2-enriched…

E’ solo effetto della chemioterapia?

La metformina non può essere considerata un farmaco…

Erneute Auswertung bestätigt alte Daten

"Signatures Genomiche " nel carcinoma duttale in situ

KEYNOTE-522 confirms ICI benefit in the neoadjuvant…

cTRAK TN: ctDNA monitoring not yet ready for primetime.…

MOLECULAR DIAGNOSTICS EBC: ctDNA for early detection of…

TNBC EBC: What is the new neoadjuvant standard…

HER2+ EBC: Chemotherapy free regimens? Extended…

Exciting novel therapies for metastatic TNBC

TROP2 - new target for improved chemotherapy

Which patients will benefit from Pembro in metastatic…

Dato-DXd new promising ADC

Best of the year: systemic therapy

Final results of the CPS score subgroup analyses show…

Immuntherapy for high tumor mutation burden in…

Oral SERDs are efficient, but show high progression…

Elacestrant - less than we expected

Effectiveness depending on PDL1 status

Precision oncology is beneficial in certain mBC…

Chekpoint inhibition in breast cancer

Switching with molecular progress improves PFS

Robust benefit of pembroluzimab in addition to…

T-Dxd is also active in patients with brain metastasis

Very good news for endocrine resistant metastatic…

Pooled analyses shows OS benefit for most subgroups

IO + IO without resounding success in the mBC setting

My highlights of 2021 in metastatic breast cancer

Patients with BRCA2 don't show PFS benefit with CDK4/6i

3 updates - 3 new standards of care

Oral SERDs for early setting and adjuvant therapy

More good news for TDXd

Amazing period for patients with refractory metastatic…

Pioneering study of personalized medicine in advanced…

Dato-Dxd for metastatic TNBC

Activity of T-Dxd across all Her2-expressing breast…

Promising results for TNBC patients

PFS improvement with fulvestrant in patients with…

Reconfirming effect of T-DXd in patients with brain…

TDXd is very efficient in patients with brain…

Samuraciclib - new targeted therapy for luminal breast…

Résultats prometteurs dans le cancer du sein triple…

L’imaging mass cytometry può aiutare a predire…

Wegweisende Daten für die personalisierte Medizin beim…

Dato-DXd – nowy obiecujący koniugat przeciwciała i…

Checkpoint-Inhibition beim Mammakarzinom

Risultati promettenti nel tumore al seno triplo…

Elacestrant – poniżej oczekiwań

Oraler Serd wirkt, aber hohe Rate an primärer Resistenz

T-Dxd aktywny również w przerzutach do mózgu

Buone notizie per i tumori mammari endocrino resistenti

Best of the Year: Systemtherapie

TDXd zeigt große Wirksamkeit bei Hirnmetastasen

Activité du T-DXd dans les metastases cérébrales

Gepoolte Analyse zeigt OS Vorteil für fast alle…

Werden orale SERDs die Therapie mit Fulvestrant in…

Wirksamkeit in Abhängigkeit von PDL1-Stautus

È un grande momento per i pazienti con tumore mammario…

Samuracyklib – nowe leczenie celowane w rakach…

Umstellung bei molekularem Progress verlängert PFS

IO + IO ohne durchschlagenden Erfolg beim mBC

Mi retrospectiva del cáncer de mama metastático en 2021

HER2 Patientinnen mit BRCA2 Mutation haben PFS Nachteil…

Amélioration de la survie sans progression par le…

Resultados finales de los análisis de los subgrupos de…

Präzisionsonkologie funktioniert beim mBC

Neues Target für optimierte Chemotherapie

Integrating patients perspectives in metastatic breast…

MBC TNBC: Molecular tumor characteristics define the…

MBC HR+: What is the best option after a CDK4/6i…

Treatment options for patients with metastatic TNBC

Therapy of brain metastasis – can T-DXd be the new SoC?

New ADCs on the horizon for TNBC patients

Targeting rare mutations in breast cancer - is this the…